Atrium Therapeutics
RNA
162 hedge funds and large institutions have $198M invested in Atrium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 162 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
86.6% more ownership
Funds ownership: 0% → 86.6% (+87%)
94% less call options, than puts
Call options by funds: $968K | Put options by funds: $15.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.8M |
| 2 |
BlackRock
New York
|
+$16.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.1M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$8.54M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$8.47M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TM
151
Torren Management
San Diego,
California
| $53 | +$56 | +4 | New |
|
|
KFAS
152
Keating Financial Advisory Services
Manhattan,
Kansas
| $40 | +$42 | +3 | New |
|
|
BIA
153
Bell Investment Advisors
Oakland,
California
| $27 | +$28 | +2 | New |
|
|
MPWT
154
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| $27 | +$28 | +2 | New |
|
|
TWD
155
True Wealth Design
Akron,
Ohio
| $14 | +$14 | +1 | New |
|
|
BFS
156
Bare Financial Services
Gap,
Pennsylvania
| $13 | +$14 | +1 | New |
|
|
CFM
157
Cornerstone Financial Management
Burlington,
Massachusetts
| $13 | +$14 | +1 | New |
|
|
RFP
158
Root Financial Partners
Encinitas,
California
| $13 | +$14 | +1 | New |
|
|
TC
159
Truvestments Capital
Sarasota,
Florida
| $13 | +$14 | +1 | New |
|
|
CA
160
Centerpoint Advisors
Needham,
Massachusetts
| – | +$70 | +5 | New |
|
161
Bessemer Group
Woodbridge,
New Jersey
| – | +$126 | +9 | New |
|
|
C
162
Covestor
London,
United Kingdom
| – | +$183 | +13 | New |
|
RNA Hedge Fund Activity: Q1 2026 in Review
162 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q1 2026, worth a combined $198M.
Buyers outnumbered sellers: 162 funds opened new RNA positions and 0 closed out — a net gain of 162 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $21.8M.
- 162 institutional investors held Atrium Therapeutics (RNA) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $198M of Atrium Therapeutics stock for Q1 2026.
- 162 funds opened new Atrium Therapeutics positions in Q1 2026 and 0 closed out, a net change of +162 holders.
- The largest Atrium Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $21.8M added.
Based on aggregated 13F filings for Q1 2026.